Theobroma cacao improves bone growth by modulating defective ciliogenesis in a mouse model of achondroplasia.

Autor: Martin L; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Kaci N; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France.; Inovarion, Paris, France., Benoist-Lasselin C; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Mondoloni M; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Decaudaveine S; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Estibals V; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Cornille M; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Loisay L; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Flipo J; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Demuynck B; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., de la Luz Cádiz-Gurrea M; Department of Analytical Chemistry, University of Granada, Granada, Spain.; Research and Development of Functional Food Centre (CIDAF), Granada, Spain., Barbault F; Université de Paris, ITODYS, CNRS, UMR 7086, 15 rue J-A de Baïf, Paris, France., Fernández-Arroyo S; Department of Analytical Chemistry, University of Granada, Granada, Spain.; Biomedical Research Unit, Medicine and Surgery Department, Rovira i Virgili University, Tarragona, Spain., Schibler L; ALLICE, Maison Nationale des Eleveurs, Paris, France., Segura-Carretero A; Department of Analytical Chemistry, University of Granada, Granada, Spain.; Research and Development of Functional Food Centre (CIDAF), Granada, Spain., Dambroise E; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France., Legeai-Mallet L; Université de Paris, Imagine Institute, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR 1163, F‑75015, Paris, France. laurence.legeai-mallet@inserm.fr.
Jazyk: angličtina
Zdroj: Bone research [Bone Res] 2022 Jan 25; Vol. 10 (1), pp. 8. Date of Electronic Publication: 2022 Jan 25.
DOI: 10.1038/s41413-021-00177-7
Abstrakt: A gain-of-function mutation in the fibroblast growth factor receptor 3 gene (FGFR3) results in achondroplasia (ACH), the most frequent form of dwarfism. Constitutive activation of FGFR3 impairs bone formation and elongation and many signal transduction pathways. Identification of new and relevant compounds targeting the FGFR3 signaling pathway is of broad importance for the treatment of ACH, and natural plant compounds are prime drug candidate sources. Here, we found that the phenolic compound (-)-epicatechin, isolated from Theobroma cacao, effectively inhibited FGFR3's downstream signaling pathways. Transcriptomic analysis in an Fgfr3 mouse model showed that ciliary mRNA expression was modified and influenced significantly by the Indian hedgehog and PKA pathways. (-)-Epicatechin is able to rescue mRNA expression impairments that control both the structural organization of the primary cilium and ciliogenesis-related genes. In femurs isolated from a mouse model (Fgfr3 Y367C/+ ) of ACH, we showed that (-)-epicatechin eliminated bone growth impairment during 6 days of ex vivo culture. In vivo, we confirmed that daily subcutaneous injections of (-)-epicatechin to Fgfr3 Y367C/+ mice increased bone elongation and rescued the primary cilium defects observed in chondrocytes. This modification to the primary cilia promoted the typical columnar arrangement of flat proliferative chondrocytes and thus enhanced bone elongation. The results of the present proof-of-principle study support (-)-epicatechin as a potential drug for the treatment of ACH.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: